MARKETSQUIET
22 days ago
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript
SIGNALSMONITORMARKETS
What's happening
SignalsMonitor is following this as a markets story. Seeking Alpha is the outlet attached so far. The first report grouped here was at 24 Sept 2026, 17:10 UTC. 2 material updates are listed in the timeline. The headline in use is “ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease…”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
Reported by 1 outlet
- Seeking Alpha